Fisher & Paykel Healthcare Corporation Limited Stock Börse Stuttgart

Equities

FPLB

NZFAPE0001S2

Medical Equipment, Supplies & Distribution

Delayed Börse Stuttgart 02:13:41 2024-05-28 am EDT 5-day change 1st Jan Change
15.3 EUR -1.29% Intraday chart for Fisher & Paykel Healthcare Corporation Limited -1.90% +19.23%

Financials

Sales 2024 * 1.73B 1.06B 980M Sales 2025 * 1.95B 1.19B 1.1B Capitalization 16.15B 9.92B 9.13B
Net income 2024 * 258M 158M 146M Net income 2025 * 333M 204M 188M EV / Sales 2024 * 9.42 x
Net Debt 2024 * 174M 107M 98.11M Net Debt 2025 * 229M 140M 129M EV / Sales 2025 * 8.42 x
P/E ratio 2024 *
62.3 x
P/E ratio 2025 *
48.1 x
Employees -
Yield 2024 *
1.42%
Yield 2025 *
1.56%
Free-Float 91.12%
More Fundamentals * Assessed data
Dynamic Chart
New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask MT
Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea MT
JPMorgan Upgrades Fisher & Paykel Healthcare to Neutral from Underweight; Price Target is NZ$24.00 MT
New Zealand Shares Jump on Rate Cut Hopes; WasteCo Raises NZ$3 Million from Convertible Bond Offer MT
Fisher & Paykel Issues Limited Recall of Airvo Devices; Flags NZ$12 Million Hit MT
Fisher & Paykel Healthcare Corporation Limited Initiates Voluntary Limited Recall of Airvo 2 and myAirvo 2 Devices Manufactured Before 14 August 2017 CI
Fisher & Paykel Healthcare Expects NZ$1.73 FY Billion Operating Revenue MT
Fisher & Paykel Healthcare Corporation Limited Revises Earnings Guidance for the Financial Year Ending 31 March 2024 CI
New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire MT
Fisher & Paykel Healthcare's Chair to Retire MT
Fisher & Paykel Healthcare Corporation Limited Announces Board Changes CI
Morgan Stanley Adjusts Fisher & Paykel Healthcare’s Price Target to NZ$24.12 From NZ$23.12, Keeps at Equalweight MT
Morgan Stanley Adjusts Fisher & Paykel Healthcare’s Price Target to AU$22.19 From AU$21.50, Keeps at Equalweight MT
Australian shares gain as financials shine; market focus on inflation data RE
New Zealand shares snap 4-day rally but set for weekly gain; Australia closed RE
More news

Latest transcript on Fisher & Paykel Healthcare Corporation Limited

1 week-1.90%
Current month-0.64%
1 month+3.33%
3 months+12.32%
6 months+30.25%
Current year+19.23%
More quotes
1 week
15.30
Extreme 15.3
15.80
1 month
15.20
Extreme 15.2
16.30
3 years
10.20
Extreme 10.2
20.40
5 years
8.43
Extreme 8.427
22.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 84-12-31
Director of Finance/CFO - 19-02-28
Chief Tech/Sci/R&D Officer - 06-12-31
Members of the board TitleAgeSince
Director/Board Member 66 90-04-30
Chairman - 15-09-30
Chief Executive Officer 63 84-12-31
More insiders
Date Price Change
24-05-28 15.3 -1.29%
24-05-27 15.5 +0.65%
24-05-24 15.4 -1.28%
24-05-23 15.6 -1.27%
24-05-22 15.8 +1.94%

Delayed Quote Börse Stuttgart, May 28, 2024 at 02:13 am EDT

More quotes
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The Company provides medical device products and systems for use in both hospital and homecare settings. Its hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, anesthesia, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include its continuous positive airway pressure (CPAP) therapy masks as well as flow generators, interfaces, and data management technologies. The Company’s products are sold in over 120 countries worldwide. It operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India and others.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
27.66 NZD
Average target price
24.65 NZD
Spread / Average Target
-10.88%
Consensus